Testing

In the first quarter of 2025, Mayo Clinic Laboratories expanded its test catalog with several innovative new tests.

Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' SPAS test identifies the form of arsenic present in patients with arsenic exposure. That information is important for determining the potential level of harm and for removing the patient from the arsenic source to ease symptoms and prevent cancer risk.

Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in survival of the transplanted organ.

Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal management of this serious kidney disease.

This will be the last CPT Codes and LOINC update. Read why.

Mayo Clinic Laboratories (MCL) is pleased to announce an essential update to our CPT code communication process and website layout. This change is designed to bring timely notifications for accurate billing information.

This page lists updates posted to Mayo Clinic Labs during the month of November.

The Lupus Foundation of America estimates that at least five million people worldwide have a form of lupus. Yet, the most widely used laboratory tests for patients with this complex condition were developed more than 60 years ago, and physicians need modern, evidence-based tools to provide high-quality care for their patients. That is why Mayo Clinic Laboratories and Progentec Diagnostics joined forces to provide solutions that transform that experience.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss how labs can enhance patient access to improve health equity.

John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.

William Morice II, M.D., Ph.D., president and chief executive officer of Mayo Clinic Laboratories, recently shared with the Advisory Board his insight into the potential that digital pathology and out-of-lab testing can bring into the laboratory space.

This page lists updates posted to Mayo Clinic Labs during the month of October.

Dr. Dong Chen and Dr. Sounak Gupta joined the “Becker’s Healthcare Podcast” to discuss the molecular testing space and its important role in personalized cancer treatment. Dr. Chen and Dr. Gupta highlighted the importance of selecting the right molecular tests for patients, the impact of genetic testing on cancer diagnosis and treatment, and how Mayo Clinic Laboratories is helping physicians make informed decisions for the best patient outcomes.